Clinical trial · Interventional
Ketamine Associated With Opioids in Refractory Cancer Pain Treatment
Efficacy of Low Analgesic Doses of Ketamine Associated With Opioids in Refractory Cancer Pain Treatment
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Long-term opioid therapy is commonly administered for the management of severe cancer pain. Increasing doses of opioids are titrated against effects until analgesia is achieved or intolerable adverse effects occur. Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has been reported to improve analgesia in patients with uncontrolled pain receiving high doses of opioids. This study aims at determining the effectiveness of ketamine as an adjuvant to opioids in relieving cancer pain.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pain | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ketamine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- 1
- description
- Ketamine
- interventionNames
- Drug: Ketamine
- type
- EXPERIMENTAL
- label
- 2
- description
- Ketamine
- interventionNames
- Drug: Ketamine
Primary outcomes (1)
- measure
- Daily pain score on an 11-point numerical pain rating scale
- timeFrame
- after 4 days
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Hospitalised cancer patients (informed and conscious of the cancer diagnostic) * Undergoing opioid treatment for one month at least * Refractory pain (score higher than 5 on an 11-point numerical pain rating scale) * Ability to score pain on a numerical pain rating scale * Patient written agreement Exclusion Criteria: * Ketamine contraindications * Methadone or other NMDA-antagonist treatment * Karnofsky index under 10 * Pregnancy
References
Publications (0)
Data not yet available